Identifying patients who will benefit the most from ADAM10 inhibition therapy should be the priority, as well as applying ADAM10 inhibitors to prevent resistance of the tumor to standard treatments such as anti-CD30 or anti-HER2. Here, TNFRSF8 is linked to neoplasm.